Virtual clinical trials now being used to fast-track drug development during coronavirus crisis

Other prominent start-ups in the space include Science 37, a full-service virtual trial platform, and Unlearn.AI, a service that creates digital twins of patients to expand data sets. In April, Unlearn.A1 received $12 million in Series A financing led by 8VC.

The U.S. Food and Drug Administration also helped clear the path to virtual trials in March by issuing guidelines for clinical studies during the pandemic that included “evaluating alternative methods for assessments, like phone contacts or virtual visits, and offering additional safety monitoring for those trial participants who may no longer have access to investigational product or the investigational site.”

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

Part 3: Innovation in Clinical Research: AI-based Drug Development Tools and the Regulatory Landscape‍

Webinars

Part 2: Faster, More Efficient Trials: Novel Trial Designs using Digital Twins‍

Webinars

Part 1: AI, Digital Twins, and the Future of Clinical Research‍

Learn about how Digital Twins are created and how they are incorporated into clinical trials to increase power, accelerate timelines, and enable patient level insights.
Watch an overview of specific use cases for Digital Twins and learn how novel trial designs with Digital Twins enable smaller trials that maintain their power.
Watch a panel discussion on the regulatory landscape where experts share perspectives on the future of AI-based drug development tools like Digital Twins.